Endocrinology and Metabolism

The Korean Endocrine Society (대한내분비학회)
권호 표지

Pharmacological Treatment of Obesity

비만의 약물 치료

Yoo, Soon-Jib
유순집

  • Published : 20080800
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 404:661-671, 2000 https://doi.org/10.1038/35007534
  2. National Task Force on the Prevention and Treatment of Obesity: Overweight, obesity, and health risk. Arch Intern Med 160:898-904, 2000 https://doi.org/10.1001/archinte.160.7.898
  3. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997 https://doi.org/10.2337/diacare.20.4.537
  4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Finnish Diabetes Prevention Study Group.Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001 https://doi.org/10.1056/NEJM200105033441801
  5. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M: The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21:1720-1725, 1998 https://doi.org/10.2337/diacare.21.10.1720
  6. Diabetes Prevention Program (DPP) Research Group: The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 25:2165-2171, 2002 https://doi.org/10.2337/diacare.25.12.2165
  7. Plodkowski RA, St Jeor ST: Medical nutrition therapy for the treatment of obesity. Endocrinol Metab Clin North Am 32:935-969, 2003 https://doi.org/10.1016/S0889-8529(03)00077-X
  8. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy in the management of obesity. JAMA 276:1907-1915, 1996 https://doi.org/10.1001/jama.276.23.1907
  9. Yanovski SJ, Yanovski JA: Obesity. N Engl J Med 346:591-602, 2002 https://doi.org/10.1056/NEJMra012586
  10. WHO Western Pacific Region, International Association for the Study of Obesity, International Obesity Task Force: The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. pp. 15-21, Sydney, Australia, Health Communications Australia, 2000
  11. Hensrud DD: Pharmacotherapy for obesity. Med Clin North Am 84:463-476, 2000 https://doi.org/10.1016/S0025-7125(05)70231-5
  12. Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71-77, 2007 https://doi.org/10.1016/S0140-6736(07)60033-6
  13. Bray GA: Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann Intern Med 119:707-713, 1993 https://doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00016
  14. Weintraub M, Hasday JD, Mushlin AI, Lockwood DH: A double-blind clinical trial in weight control: use of fenfluramine and phentermine alone and in combination. Arch Intern Med 144:1143-1148, 1984 https://doi.org/10.1001/archinte.144.6.1143
  15. Wong DT, Bymaster FP, Engleman EA: Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57:411-441, 1995 https://doi.org/10.1016/0024-3205(95)00209-O
  16. Stock, MJ: Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes 21(Suppl 1): S25-S29, 1997
  17. Ryan DH: Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. Endocrine 13:193-199, 2000 https://doi.org/10.1385/ENDO:13:2:193
  18. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A: The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 23:1016-1024, 1999 https://doi.org/10.1038/sj.ijo.0801059
  19. Walsh KM, Leen E, Lean ME: The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int J Obes Relat Metab Disord 23:1009-1015, 1999 https://doi.org/10.1038/sj.ijo.0801045
  20. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP; Sibutramine/Diabetes Clinical Study Group: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2:175-187, 2000 https://doi.org/10.1046/j.1463-1326.2000.00081.x
  21. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2:105-112, 2000 https://doi.org/10.1046/j.1463-1326.2000.00071.x
  22. McNulty SJ, Ur E, Williams G; Multicenter Sibutramine Study Group: A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26:125-131, 2003 https://doi.org/10.2337/diacare.26.1.125
  23. Sharma AM: Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat Metab Disord 24(Suppl. 4):S20-S23, 2001 https://doi.org/10.1038/sj.ijo.0801079
  24. Hazenberg BP: Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94:152-158, 2000 https://doi.org/10.1159/000047310
  25. Fanghanel G, Cortinas L, Sanchez-Reyes L, Gomez -Santos R, Campos-Franco E, Berber A: Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv Ther 20:101-113, 2003 https://doi.org/10.1007/BF02850257
  26. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM: Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes Relat Metab Disord 29:509-516, 2005 https://doi.org/10.1038/sj.ijo.0802887
  27. Heck AM, Yanovski JA, Calis KA: Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20:270-279, 2000 https://doi.org/10.1592/phco.20.4.270.34882
  28. Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB: Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281:235-242, 1999 https://doi.org/10.1001/jama.281.3.235
  29. Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21:1288-1294, 1998 https://doi.org/10.2337/diacare.21.8.1288
  30. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS: Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 31:53-65, 2008 https://doi.org/10.2165/00002018-200831010-00005
  31. Hiley CR, Ford WR: Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev Camb Philos Soc 79:187-205, 2004 https://doi.org/10.1017/S1464793103006201
  32. De Petrocellis L, Cascio MG, Di Marzo V: The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765-774, 2004 https://doi.org/10.1038/sj.bjp.0705666
  33. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation, Nat Rev Drug Discov 3:771-784, 2004 https://doi.org/10.1038/nrd1495
  34. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance, Nat Neurosci 8:585-589, 2005 https://doi.org/10.1038/nn1457
  35. Osei-Hyiaman D, De Petrillo M, Pacher P, Piu J, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305, 2006
  36. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617, 2002 https://doi.org/10.1523/JNEUROSCI.22-21-09612.2002
  37. Onaivi ES, Leonard CM, Ishiguro H, Zhang PW, Lin Z, Akinshola BE, Uhl GR: Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 66:307-344, 2002 https://doi.org/10.1016/S0301-0082(02)00007-2
  38. Boyd ST, Fremming BA: Rimonabant: a selective CB1 antagonist. Ann Pharmacother 39:684-690, 2005 https://doi.org/10.1345/aph.1E499
  39. Gary-Bobo M, Elachouri G, Scatton G, Le Fur G, Oury-Donat F, Bensaid M: The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471-478, 2006 https://doi.org/10.1124/mol.105.015040
  40. Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ, Lu K, Yuan J, Sanabria-Bohorquez SM, Stoch A, Stevens C, Fong TM, De Lepeleire I, Cilissen C, Cote J, Rosko K, Gendrano IN 3rd, Nguyen AM, Gumbiner B, Rothenberg P, de Hoon J, Bormans G, Depré M, Eng WS, Ravussin E, Klein S, Blundell J, Herman GA, Burns HD, Hargreaves RJ, Wagner J, Gottesdiener K, Amatruda JM, Heymsfield SB: The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68-78, 2008 https://doi.org/10.1016/j.cmet.2007.11.012
  41. Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J: Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 48;418-427, 2008 https://doi.org/10.1177/0091270008314467
  42. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S, RIO-Europe Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397, 2005 https://doi.org/10.1016/S0140-6736(05)66374-X
  43. Despres JP, Golay A, Sjostrom L: Rimonabant in Obesity-Lipids Study Group: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134, 2005 https://doi.org/10.1056/NEJMoa044537
  44. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, RIO-North America Study Group: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761-775, 2006 https://doi.org/10.1001/jama.295.7.761
  45. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368:1660-1672, 2006 https://doi.org/10.1016/S0140-6736(06)69571-8
  46. Oh I, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M: Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443:709-712, 2006 https://doi.org/10.1038/nature05162
  47. Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ, Williams SC: PYY modulation of cortical and hypothalamic brain areas predicts feeding behaviour in humans. Nature 450:106-109, 2007 https://doi.org/10.1038/nature06212
  48. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A: Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 293:E604-E609, 2007 https://doi.org/10.1152/ajpendo.00153.2007
  49. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, MacNeil DJ, Heymsfield SB, Amatruda JM: Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92:1754-1757, 2007 https://doi.org/10.1210/jc.2006-1806
  50. Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB: NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine. Obesity (Silver Spring) 15:2027-2042, 2007 https://doi.org/10.1038/oby.2007.242
  51. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S: Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 341:879-884, 1999 https://doi.org/10.1056/NEJM199909163411204
  52. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568-1575, 1999 https://doi.org/10.1001/jama.282.16.1568
  53. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, Farid AR, Smith FJ, Campfield LA: Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 85:4003-4009, 2000 https://doi.org/10.1210/jc.85.11.4003
  54. Bessesen DH: Update on obesity. J Clin Endocrinol Metab 93:2027-2034, 2008 https://doi.org/10.1210/jc.2008-0520
  55. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581-588, 1997 https://doi.org/10.1056/NEJM199708283370901
  56. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343:1826-1832, 2000 https://doi.org/10.1056/NEJM200012213432501
  57. Haller CA, Benowitz NL: Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med 343:1833-1838, 2000 https://doi.org/10.1056/NEJM200012213432502
  58. Sharma AM: Sibutramine in overweight/obese hypertensive patients. Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 4:S20-S23 https://doi.org/10.1038/sj.ijo.0801934
  59. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356:2119-2125, 2000 https://doi.org/10.1016/S0140-6736(00)03491-7
  60. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:155-161, 2004 https://doi.org/10.2337/diacare.27.1.155
  61. Kelley DE, Kuller LH, McKolanis TM, Harper P, Mancino J, Kalhan S: Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 27:33-40, 2004 https://doi.org/10.2337/diacare.27.1.33
  62. Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P; SCOUT Investigators: Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 28:2915-2923, 2007 https://doi.org/10.1093/eurheartj/ehm217
  63. Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP; SCOUT Investigators: Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes Obes Metab 2008 Jul 29. [Epub ahead of print]
  64. Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes(CRESCENDO). ClinicalTrials.gov Identifier: NCT00263042 (sanofi-aventis). http://clinicaltrials.gov/ct/show/NCT00263042